Ocera Forwards Liver Disease Drug After Reverse Merger With Tranzyme
This article was originally published in The Pink Sheet Daily
Executive Summary
Ocera went public by completing a reverse merger with the failing biotech Tranzyme, then completed a $20 million PIPE financing that positions it to begin a Phase IIb trial studying its lead drug for a rare liver disease.